ITL #704 Data, digital influence and credibility: building the future of Healthcare PR in Brazil

1 hour, 18 minutes ago

Using big data and digital influence to foster dialogue among industry, the media, healthcare professionals and patients. By Renata Saraiva.



The surge in interest in health and self-care in Brazil following COVID-19 has reshaped public relations practice in the healthcare sector.

A Vox Populi/IESS survey conducted in October 2025 found that 60% of Brazilians seek health information online. Among them, nine in ten identify Google as their primary starting point for information on symptoms, diseases, diagnoses and treatments.

The survey also found that 19% of respondents use generative artificial intelligence (AI) to find and interpret health information. Yet alongside the growing role of digital channels, the findings reveal a trust gap: most respondents do not fully trust the information they find.

In traditional media, leading national outlets have launched specialist health titles, including Forbes Saúde, Veja Saúde and Pulsa, from O Estado de S. Paulo. Healthcare professionals, meanwhile, have substantially expanded their use of social media to communicate directly with patients and, in some specialties, with their peers.

Big data and digital influence

This changing landscape has expanded the role of PR beyond awareness campaigns and expert commentary in major media outlets. Big data and digital influence now offer additional ways to foster dialogue among industry, the media, healthcare professionals and patients.

Around two years ago, we conducted an in-depth study of Brazilian digital opinion leaders (DOLs) in ophthalmology for a client that is a global leader in eye-care equipment and pharmaceuticals. We identified 102 leading digital influencers in the field: specialists who communicate with both patients and fellow professionals, with the latter audience being our client's priority. We shortlisted 30 specialists and, together with the client, selected 15 for the first year of our stakeholder engagement programme, alongside the company's established key opinion leaders (KOLs).

The DOL programme became an integral part of ongoing communications and PR. Monthly and quarterly social media analyses showed that reach and engagement generated through what we call medical earned media contributed significantly to the increase in our client's share of voice in the third quarter of 2026. Share of voice reached 37%, up from 35% in each of the first two quarters.

These results came from extending practices previously reserved for media relations to engagement with KOLs and DOLs: inviting them to briefings on innovative ophthalmic technologies, sharing content and playbooks offering social media guidance, and involving them in medical education events. All activities complied with the code of ethics of Brazil's Federal Council of Medicine and the company's compliance guidelines.

The DOL project also revealed a surprising insight into specialists' presence on social media platforms in Brazil. Contrary to what the company had previously believed, DOLs have a stronger presence on platforms such as Instagram and TikTok than on LinkedIn. This trend mirrors the distribution of users across social networks in Brazil. The country, which has the largest social media presence in Latin America, with 150 million users (70.4% of the population), has 147 million Instagram followers and 131 million TikTok users (source: Digital 2026: Brazil, by Meltwater in partnership with We Are Social).

Projects such as the DOL initiative, in which a reciprocal relationship between industry and its key stakeholders—specialists—places value on accurate scientific information, strengthen the credibility of health information in the digital world, extending beyond that relationship to reach patients as well.

Reach and credibility

For clients in consumer hygiene and healthcare products, we have also seen the impact of partnering with healthcare professionals who have a digital presence as part of an integrated content and influence strategy that also includes GEO, SEO and traditional PR. These initiatives rely less on big data, but are no less rigorous in their attention to information quality and credibility.

A global leader in adult urinary incontinence products, TENA, a brand of Swedish company Essity, has made raising public awareness and breaking taboos around the subject one of its missions. A topic that was virtually invisible just four or five years ago is now discussed far more openly in Brazilian digital media, thanks to the gynaecologists, urologists, psychologists, oncologists and nurses with varying levels of digital presence whom we have been engaging to discuss it as part of the brand's communications—whether on their own social channels (medical earned media), the brand's channels (owned media) or in the press (traditional earned media).

The future of healthcare communications and public relations will increasingly be driven by integrated data and digital influence strategies. Big data makes it possible to identify relevant voices, understand behaviours, recognise opportunities for dialogue and measure results more precisely. But turning information into reputation requires more than reach, engagement or share of voice: it requires credibility.

In this context, KOLs and DOLs become strategic partners in disseminating scientific knowledge, provided their relationship with industry is grounded in transparency, professional independence and respect for ethical standards. Medical codes of ethics and market-specific regulations must guide these initiatives, while industry compliance programmes must ensure that relationships with healthcare professionals neither compromise their autonomy nor turn scientific content into disguised promotion.

For PR teams, the challenge is to integrate data, digital influence, traditional media and owned channels into strategies that broaden access to reliable information and contribute to health education. This requires clear criteria for selecting spokespeople, content governance and ongoing evaluation of results.

In an environment marked by misinformation, sustainable competitive advantage will lie not merely in reaching more people, but in earning their trust. It is at this intersection of data intelligence, ethical responsibility and commitment to society that healthcare PR can create value for brands, professionals and, above all, patients.


author"s portrait

The Author

Renata Saraiva

Renata Saraiva is the founder and CEO of Truly, an independent Brazilian communications and PR agency. With extensive consulting experience across a range of sectors, she served as Group Director at The Jeffrey Group and, for ten years, as Managing Director of Ogilvy PR. In these roles, she led teams serving Brazilian and multinational companies, government bodies and non-governmental organisations. Truly combines the seniority of its leadership with the use of data intelligence, creativity and technology to generate tailor-made solutions for its clients.

mail the author
visit the author's website



Forward, Post, Comment | #IpraITL

We are keen for our IPRA Thought Leadership essays to stimulate debate. With that objective in mind, we encourage readers to participate in and facilitate discussion. Please forward essay links to your industry contacts, post them to blogs, websites and social networking sites and above all give us your feedback via forums such as IPRA’s LinkedIn group. A new ITL essay is published on the IPRA website every week. Prospective ITL essay contributors should send a short synopsis to IPRA head of editorial content Rob Gray email



Welcome to IPRA


Authors

Archive

July (4)
June (5)
May (4)
July (4)
June (5)
May (4)
July (5)
June (4)
May (4)
July (5)
June (4)
May (5)
July (4)
June (4)
May (5)
July (4)
June (4)
May (5)
July (4)
June (5)
May (4)
July (5)
June (4)
May (4)
July (5)
June (4)
May (4)
July (5)
June (4)
May (5)
July (3)
June (4)
May (5)
July (4)
June (5)
May (5)
July (5)
June (4)
May (4)
July (4)
June (3)
May (3)
June (8)
June (17)
March (15)
June (14)
April (20)
June (16)
April (17)
June (16)
April (13)
July (9)
April (15)
Follow IPRA: